Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024

This “Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Inhibitor Of Apoptosis (IAP) Antagonist Understanding

Inhibitor Of Apoptosis (IAP) Antagonist: Overview

Inhibitors of Apoptosis (IAPs) are a family of proteins with various biological functions including regulation of innate immunity and inflammation, cell proliferation, cell migration and apoptosis. They are characterized by the presence of at least one N-terminal baculoviral IAP repeat (BIR) domain involved in protein-protein interaction. Inhibitor of apoptosis proteins (IAPs) is a class of key apoptosis regulators that promote cancer cell resistant to apoptosis, particularly in cancer treatment. Disrupting the binding of IAPs with their functional partners therefore is a promising strategy to restore the apoptotic response to proapoptotic stimuli, particularly those introduced by standard cancer therapies. Inhibitor of apoptosis proteins (IAPs) play a major role in determining whether cells undergo apoptosis in response to TNF as well as other stimuli. IAPs play a major role in influencing the production of multiple inflammatory mediators, arguing that these proteins are important regulators of inflammation in addition to apoptosis. Furthermore, small molecule IAP antagonists can modulate spontaneous as well as TNF-induced inflammatory responses, which may have implications for use of these agents in therapeutic settings. Defects in apoptosis regulation are one main cause of cancer development and may result from overexpression of anti-apoptotic proteins such as inhibitor of apoptosis proteins (IAPs). IAPs represent possible targets for specifically neutralizing therapy resistance mechanisms that lead to therapy failure and relapse. XIAP on one hand inhibits cell death execution by physical interaction with caspases and by causing their proteasomal degradation, on the other hand it also triggers survival signaling via the NF?B pathway thereby directly shifting the survival/death balance in cancer cells toward death resistance and NF?B-driven survival. The results from a plethora of preclinical studies, which demonstrate that XIAP-antagonists prove efficacy in enhancing drug- and radiotherapy-related cancer cell death and in specific cancer types even cause tumor remission are very promising. Therefore, in combination with diagnostic methods to identify patient subgroups that benefit from these novel compounds, XIAP-antagonists may be developed into highly efficient drugs in personalized medicine to overcome therapy resistance in cancer treatment.

Inhibitor of Apoptosis (IAP) Antagonist- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inhibitor of Apoptosis (IAP) Antagonist pipeline landscape is provided which includes the disease overview and Inhibitor of Apoptosis (IAP) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inhibitor of Apoptosis (IAP) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inhibitor of Apoptosis (IAP) Antagonist R&D. The therapies under development are focused on novel approaches to treat/improve Inhibitor of Apoptosis (IAP) Antagonist.

Inhibitor of Apoptosis (IAP) Antagonist Emerging Drugs Chapters

This segment of the Inhibitor of Apoptosis (IAP) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inhibitor of Apoptosis (IAP) Antagonist Emerging Drugs

Xevinapant: Debiopharm/Merck Xevinapant, now under an exclusive license agreement with Merck for product development and commercialization, is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). As leader of the class of IAP inhibitors, xevinapant established proof of efficacy in high-risk locally advanced squamous cell carcinoma of the head and neck (LASCCHN) patients for which the combination provided highly significant and sustainable clinical benefit as compared to CRT alone. In addition to combination with CRT, xevinapant is also being investigated in combination with chemotherapy as well as checkpoint inhibitors. The IAPs work to help tumor cells to escape from this controlled, cell death pathway and thus survive and proliferate. By inhibiting IAPs, Xevinapant enhances the killing of cancer cells by CRT, facilitating the destruction of the tumor. In addition, pre-clinical studies have shown a direct enhancement T lymphocyte activation, revealing the compound’s dual mode of action. An exclusive license agreement has been granted to Merck in 2021 for its further development andcommercialization.

ASTX 660: Astex Pharmaceuticals Tolinapant is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (c IAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism which works to enhance an anti-tumor immune response in T-cell lymphomas. Tolinapant was designed using Astex’s fragment-based drug designtechnology.

Inhibitor of Apoptosis (IAP) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Inhibitor of Apoptosis (IAP) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inhibitor Of Apoptosis (IAP) Antagonist

There are approx. 6+ key companies which are developing the therapies for Inhibitor of Apoptosis (IAP) Antagonist. The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inhibitor of Apoptosis (IAP) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inhibitor of Apoptosis (IAP) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inhibitor of Apoptosis (IAP) Antagonist drugs.

Inhibitor of Apoptosis (IAP) Antagonist Report Insights

• Inhibitor Of Apoptosis (IAP) Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Inhibitor Of Apoptosis (IAP) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Inhibitor of Apoptosis (IAP) Antagonist drugs?
• How many Inhibitor of Apoptosis (IAP) Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inhibitor of Apoptosis (IAP) Antagonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inhibitor of Apoptosis (IAP) Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Inhibitor of Apoptosis (IAP) Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co.
• Novartis Pharmaceuticals
• Astex Pharmaceuticals
• Ascentage Pharma Group Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Key Products

• Xevinapant
• LCL 161
• ASTX 660
• APG-1387
• TQB3728